Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | UHRF1 | Q96T88 | 4/20 | 0.51 |
| ▸ | APEX1 | P27695 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14788110 | 0.90 | KDM4E (0.56) | KDM4ERAB9AMEN1KMT2AMAPT | |
| SCHEMBL13833761 | 0.84 | KDM4E (0.44) | KDM4ERAB9AMEN1KMT2AMAPT | |
| SCHEMBL13833860 | 0.83 | KDM4E (0.48) | KDM4ERAB9AMEN1KMT2AMAPT | |
| SCHEMBL13833745 | 0.81 | MMP13 (0.42) | KDM4ERAB9AMEN1KMT2AMAPT | |
| SCHEMBL13833744 | 0.77 | APEX1 (0.61) | KDM4ERAB9AMEN1KMT2AMAPT | |
| SCHEMBL14788072 | 0.76 | MAPT (0.53) | KDM4ERAB9AMEN1KMT2AMAPT | |
| SCHEMBL14788101 | 0.73 | MAPT (0.48) | KDM4ERAB9AMEN1KMT2AMAPT | |
| SCHEMBL14788074 | 0.72 | KDM4E (0.53) | KDM4ERAB9AMEN1KMT2AMAPT | |
| SCHEMBL3524858 | 0.70 | PDK2 (0.42) | RAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL13833687 | 0.70 | KDM4E (0.47) | KDM4ERAB9AMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2013-03-21 | — | — | US | disclosed |
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2013-03-21 | — | — | US | disclosed |
| WO-2012154888-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072473-A1 | COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS | HSPA5, PSMG3, VCP | KDM4E 3155/4885RAB9A 858/4885MEN1 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.